Novavax Appoints Bob Darius Senior Vice President, Quality Operations

GAITHERSBURG, Md., March 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Bob Darius, Senior Vice President, Quality Operations. He will be responsible for leading the global Quality Operations of the company, including both Quality Assurance and Quality Control, as well as serving as a member of the company’s senior management team.

Mr. Darius joins Novavax with over 25 years of experience in Quality Assurance, Quality Control and strategic manufacturing. As VP Quality Operations at GlaxoSmithKline (GSK) Biologicals, he provided oversight of the North American and German Vaccine Manufacturing Operations for over 10 years and most recently transitioned to Head Quality Advocacy Liaison. Mr. Darius also held positions of increasing responsibility at the Food and Drug Administration, Center for Biologics Evaluation and Research, where he was a Senior Reviewer and Inspector, Advisor to the Deputy Center Director, Medicine, on counter-bioterrorism products. He earned a Bachelor of Science degree in Biology from George Mason University and completed graduate work in biotechnology at Johns Hopkins University.

“I am delighted to welcome Bob to the Novavax team,” said Stanley C. Erck, President and CEO. “At this critical stage of our development, during which we are implementing our commercialization plans for our RSV F Vaccine, Bob’s depth of experience and understanding of evolving regulatory and quality requirements will be critical to our success.”

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:

Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
[email protected]
240-268-2000